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Objectives. This study sought to compare the efficacy of 2-h
regimens of alteplase and streptokinase in acute massive pulmo-
nary embolism. The primary end point was immediate hemody-
namic improvement, and secondary end points included early
clinical efficacy and safety, as well as 1-year clinical outcome.
Background. Several thrombolytic regimens have been com-
pared for the past 10 years in randomized studies, showing that
2-h infusion regimens of alteplase or urokinase lead to faster
hemodynamic improvement than former 12- to 24-h administra-
tion protocols in acute massive pulmonary embolism. Many trials
have focused on immediate hemodynamic and angiographic out-
comes, but none has addressed long-term follow-up after throm-
bolysis.
Methods. Sixty-six patients with acute massive pulmonary
embolism (Miller score >17 and mean pulmonary artery pressure
>20 mm Hg) were randomly assigned to receive either a 100-mg
2-h infusion of alteplase (n 5 23) or 1.5 million IU of streptoki-
nase over 2 h (n 5 43). In both groups, heparin infusion was
started at the end of thrombolytic infusion and adapted thereaf-
ter. Total pulmonary resistance was monitored over a 12-h period.
Pulmonary vascular obstruction was assessed 36 to 48 h after
thrombolytic therapy. One-year follow-up information included
death, cause of death, recurrent pulmonary embolism, chronic
thromboembolic pulmonary hypertension, stroke and bleeding.
Results. Both groups had similar baseline angiographic and
hemodynamic characteristics of severity, with maintained cardiac
output in 64 (97%) of 66 patients. The results (mean 6 SD)
demonstrated that despite a faster total pulmonary resistance
improvement observed at 1 h in the alteplase group compared
with the streptokinase group (33 6 16% vs. 19 6 16%, p 5 0.006),
a similar hemodynamic efficacy was obtained at 2 h when both
thrombolytic regimens were completed (38 6 18% vs. 31 6 19%).
There was no significant difference in either pulmonary vascular
obstruction at 36 to 48 h or bleeding complication rates. One-year
event-free survival was similar in both groups, as most events were
related to concomitant diseases.
Conclusions. These results suggest that a 2-h regimen of
streptokinase can be routinely used in patients with massive
pulmonary embolism and maintained cardiac output without
obviously compromising efficacy or safety.
(J Am Coll Cardiol 1998;31:1057–63)
©1998 by the American College of Cardiology
Thrombolysis is widely accepted as the treatment of choice for
acute massive life-threatening pulmonary embolism, defined as
severe pulmonary vascular obstruction resulting in hemody-
namic instability. In this condition, thrombolytic therapy has
been proved to clear pulmonary artery thrombus and improve
hemodynamic status faster than does intravenous heparin
(1–4). Moreover, it has been very recently reported from
registry data that early thrombolytic treatment may reduce
in-hospital overall mortality and recurrence of pulmonary
embolism, at the cost of an increased rate of major bleeding
episodes (5). Several thrombolytic regimens have been com-
pared for the last 10 years in randomized studies, showing that
2-h infusion regimens of alteplase or urokinase lead to faster
hemodynamic improvement compared with former 12- to 24-h
administration protocols (6–8). Moreover, a bolus injection of
alteplase was found to be neither more efficient nor safer than
a 2-h infusion (9,10).
Newer generation thrombolytic agents such as alteplase are
commonly used in clinical practice. However, a recent random-
ized trial comparing a 100-mg 2-h infusion of alteplase with 1.5
million IU of streptokinase over 12 h clearly demonstrated that
hemodynamic improvement occurred more rapidly in the
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alteplase group, but with no further significant difference at 6
and 12 h when both thrombolytic infusions were completed
(11). In addition, in a recent small randomized trial, a signifi-
cant reduction in mortality rate was observed with intravenous
streptokinase as compared with heparin in life-threatening,
massive pulmonary embolism (12). Furthermore, the third
International Study of Infarct Survival (ISIS-3) and the Global
Utilization of Streptokinase and TPA for Occluded arteries
(GUSTO) trial have shown that streptokinase induced fewer
bleeding complications than did alteplase and anistreplase
(13,14). Hence, streptokinase remains worthwhile for throm-
bolysis in acute massive pulmonary embolism.
Therefore, the aim of the trial was to compare the efficacy
of 2-h regimens of alteplase and streptokinase in acute massive
pulmonary embolism. The primary end point was immediate
hemodynamic improvement, and secondary end points in-
cluded early clinical efficacy and safety, as well as 1-year
clinical outcome.
Methods
This study was a single-blind randomized trial conducted in
four French centers.
Patient selection. Any patient .18 years old who was
referred for recent symptoms (,5 days) suggestive of acute
massive pulmonary embolism was considered for entry into the
study. After routine clinical examination, patients were re-
ferred to the catheterization laboratory for pulmonary angiog-
raphy. Thrombolytic therapy was administered after informed
consent was obtained, if the Miller score was .17/34 and if the
mean pulmonary artery pressure (MPAP) was .20 mm Hg
regardless of clinical presentation.
Exclusion criteria included 1) significant preexisting cardio-
pulmonary disease; 2) recent puncture of a noncompressible
vessel or organ biopsy; 3) recent application of a vena cava
filter or current treatment with Coumadin; 4) pregnancy,
puerperium or lactation; 5) head trauma or cerebrovascular
accident within the past 6 months; 6) history of cerebral
hemorrhage, intracranial or intraspinal surgery; 7) bleeding
disorder or platelet count ,100,000/mm3 on admission; 8)
proliferative or hemorrhagic diabetic retinopathy; 9) systolic
blood pressure .180 mm Hg or diastolic blood pressure
.110 mm Hg, or both; 10) known dissecting or other aneu-
rysms; 11) major operation or trauma within the past 10 days;
12) known pericarditis or endocarditis; 13) occurrence of
allergic reactions, severe hypotension or cardiac arrest during
initial pulmonary angiography; 14) gastrointestinal bleeding
within the previous year; and 15) recent external cardiac
resuscitation maneuvers.
Pulmonary angiography. Selective right and left pulmo-
nary angiography was performed, preferably through the bra-
chial venous access, before initiation of thrombolytic treat-
ment. Standard large-format cut-film angiography or 35-mm
cine films were used. Each pair of coded angiograms was
reviewed by a panel of two experienced readers who were
unaware of the chronologic order of the angiograms and study
treatment. Severity of embolism was assessed using the method
of Miller et al. (15). The individually allocated scores were
reviewed by the panel and a consensus score was derived.
Hemodynamic measurements. MPAP was recorded before
the first pulmonary angiogram. After enrollment in the study,
serial measurements of heart rate, respiratory rate, systolic,
diastolic and mean pulmonary artery pressures and cardiac
output (CO) were done before initiation of thrombolysis and at
30 min and 1, 2, 6 and 12 h by means of a five-way Swan-Ganz
thermodilution catheter with a rapid-response thermistor in-
serted into the pulmonary artery immediately after the initial
pulmonary angiogram (Edwards 93A-431H-7.5 F). Total pul-
monary resistance (TPR) was derived as TPR 5 (MPAP/CO) 3
80 in dyneszcm25zs, with CO in liters/min and MPAP in mm Hg.
Medication. After providing informed consent, patients
were randomly assigned to receive either alteplase or strep-
tokinase on a 1:2 basis. In the alteplase group, patients
received a 100-mg infusion of alteplase over a 2-h period,
10 mg of which was injected as a bolus. For patients weighing
,65 kg, the dose was reduced to 70 mg over 2 h, with an initial
bolus injection of 7 mg (7). In the streptokinase group, patients
received a 1.5-million IU infusion of streptokinase over 2 h. In
both groups, intravenous heparin infusion was started at the end
of thrombolytic infusion, maintained at a dose of 1,000 IU/h
and adapted to achieve an activated partial thromboplastin
time ratio of two to three times the control value. Any other
medication needed by the patient was left to the discretion of
the attending physician. The dosage of inotropic or vasoactive
drugs, if any, was maintained constant during the period of
hemodynamic measurements. Oral anticoagulant therapy was
introduced on day 5 and pursued over 6 months. Patients were
followed up to day 10 and then discharged from the hospital.
Perfusion lung scanning. Perfusion lung scans were taken
within 36 to 48 h after the onset of treatment. Six-view
ventilation and perfusion lung scans were obtained in a single
session with a high resolution, low energy, large field camera
(Sophy Camera DS7) with an inhaled spray solution of dieth-
ylenetriaminepentaacetic acid labeled with technetium-99m
for the ventilation scan and with human serum albumin
microaggregates labeled with technetium-99m for the perfu-
sion scan.
According to methods derived from the method used in the
Prospective Investigation of Pulmonary Embolism Diagnosis
Abbreviations and Acronyms
ISIS 5 International Study of Infarct Survival
GUSTO 5 Global Utilization of Streptokinase and TPA for
Occluded arteries
TPR 5 total pulmonary resistance
MPAP 5 mean pulmonary artery pressure
CO 5 cardiac output
PIOPED 5 Prospective Investigation of Pulmonary Embolism
Diagnosis
USPET 5 Urokinase Streptokinase Pulmonary Embolism Trial
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(PIOPED) study (16), lung scans were independently inter-
preted by two nuclear medicine readers who were unaware of
the patient’s treatment group and the initial angiographic
Miller score. The regional distribution of pulmonary blood
flow was divided in 18 segments, and a semiquantitative
perfusion score from 0 to 1 (0, 0.25, 0.5 and 1) was estimated
from the density by comparison with the photodensity of an
apparently normally perfused segment. The overall perfusion
score was determined by summing the perfusion scores of the
18 segments. Percent vascular obstruction was then calculated
as (18 2 Overall perfusion score) 3 100.
Hematologic and hemostatic measurements. Blood sam-
ples for determination of blood cell counts, hemoglobin and
plasma fibrinogen were taken before thrombolytic treatment
and 12, 24 and 48 h and 10 days thereafter. In addition, plasma
fibrinogen and coagulation variables were assessed at baseline
and 2, 6, 12 and 24 h after initiating thrombolysis.
Adverse events. Adverse events were noted throughout the
hospital stay. Major bleeding was prospectively defined as
bleeding that required blood transfusion, surgical control or
discontinuation of the study treatment; hemorrhagic stroke
confirmed by computed tomography or autopsy; bleeding
causing a fall of 15% in hematocrit within 72 h after the onset
of therapy; or any bleeding complications causing death. Other
important bleeding, defined as a fall of 10% in hematocrit,
such as retroperitoneal, gastrointestinal or genital bleeding,
hematomas or prolonged external bleeding at puncture sites,
hemoptysis, epistaxis and hematuria, was also recorded (9–11).
Follow-up. Patients were contacted by study coordinators
at 1 year to ascertain recurrent hospital admissions and other
study information, including death, cause of death, recurrent
pulmonary embolism, chronic thromboembolic pulmonary hy-
pertension, cancer, stroke and bleeding. In case of recurrent
hospital admission, appropriate data were abstracted from
hospital records to document the nature of end-point events.
Statistical analysis. In view of the consistent clinical data
obtained with a 2-h alteplase regimen, patients were random-
ized to receive either a 2-h alteplase infusion or a 2-h strep-
tokinase infusion in a 1:2 allocation ratio. Calculation of
sample size demonstrated that ;65 patients were required to
show a difference of 15 points between treatment groups in
percent reduction of TPR 2 h after the onset of thrombolysis,
with 80% power and a two-sided level of significance of 0.05,
assuming a standard deviation of ;20 points. Data were
analyzed according to the intention-to-treat principle.
All results are expressed as the mean value 6 SD. Categoric
data analyses were performed using the chi-square test and the
Fisher exact test (2 3 2 table). Comparison of continuous data
between both groups was performed using the unpaired Stu-
dent t test. Changes in hemodynamic measurements over time
were analyzed using repeated measures analysis of variance.
Normality was evaluated with the Shapiro-Wilk statistic
(threshold value: p 5 0.15). A p value ,0.05 was considered
significant. All reported p values were two-sided.
Ethical considerations. The study protocol was submitted
to the Ethics Committee of Hoˆpital Universitaire Saint-Jacques,
which gave formal approval for conduction of the study.
Results
Sixty-six patients were enrolled in the study: 43 received
streptokinase and 23 alteplase. There were no significant
differences between the two treatment groups in terms of
demographic and clinical characteristics (Table 1). Both
groups had similar baseline angiographic and hemodynamic
characteristics of severity, with maintained CO in 64 (97%) of
66 patients. Complete hemodynamic monitoring was obtained
in every patient. The total dose of the allocated drug was
effectively administered to 64 of 66 patients. In two patients,
injection of streptokinase was discontinued because of a
systolic blood pressure drop of #80 mm Hg during injection;
one patient received only 250,000 IU of streptokinase and the
other 1 million IU of streptokinase. Only two patients received
an inotropic agent (dobutamine in each patient at a dose of
10 mg/kg body weight per min). A perfusion lung scan was
obtained in all but one patient who required emergency
embolectomy because of a recurrent embolism.
Clinical course and adverse events (Table 2). The clinical
course was uneventful in 18 alteplase-treated patients (78%)
and in 32 streptokinase-treated patients (74%) (p 5 NS). A
significant decrease in respiratory rate was observed in both
study groups over the first 12 h (considered early symptomatic
relief), with no intergroup difference (223% in alteplase group
vs. 221% in streptokinase group; p 5 NS). No deaths occurred
in either group. Recurrent nonfatal pulmonary embolism
occurred in one streptokinase-treated patient who needed
emergency embolectomy and in two alteplase-treated patients.
A blood pressure drop of #80 mm Hg was more frequent in
the streptokinase group than in the alteplase group, but the
difference was not statistically significant. Heparin-induced
thrombocytopenia—immediately regressive and without com-
plication after introduction of oral anticoagulant agents
Table 1. Baseline Characteristics of Patients*
Alteplase
(n 5 23)
Streptokinase
(n 5 43)
Male/female 14/9 23/20
Age (years) 68 6 11 67 6 11
Heart rate (beats/min) 93 6 18 93 6 15
Syncope 8 12
Cardiogenic shock 1 1
Respiratory rate (breaths/min) 22 6 6 22 6 5
Mean pulmonary artery pressure
(mm Hg)
33 6 8 35 6 10
Cardiac output (liters/min) 4.2 6 1.4 4.1 6 1.5
Total pulmonary resistance
(dyneszcm25zs)
721 6 361 790 6 415
Miller score (34) 23 6 3 23 6 3
*p 5 NS for all comparisons. Data presented are number of patients or mean
value 6 SD.
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and discontinuation of heparin infusion—occurred in two
streptokinase-treated patients and in one alteplase-treated
patient.
At the end of the hemodynamic monitoring period, three
patients from the streptokinase group were given an additional
dose of alteplase: in the two patients previously mentioned
because of hypotension resulting in incomplete thrombolytic
infusion and in one patient because of insufficient hemody-
namic improvement as determined by the physician in charge
of the patient.
The frequency of bleeding complications was not signifi-
cantly different between the two groups, but the alteplase
group had a tendency toward more frequent major bleedings
and, conversely, less frequent important bleedings compared
with the streptokinase group.
It is important to emphasize that the majority of major
bleeding occurred at vascular access sites necessitated by
pulmonary angiography despite a cautious vascular approach.
Access sites were equally distributed between the femoral and
humeral approach (33 vs. 33). However, five of the six major
bleeding complications related to vascular access occurred with
the femoral approach (83%).
Hemodynamic and lung scan results (Table 3). Over the
12 h of hemodynamic monitoring, a significant increase from
baseline values occurred in both treatment groups with regard
to CO (14 6 10% vs. 23 6 12% in alteplase and streptokinase
groups, respectively) and mixed venous blood hemoglobin
saturation (11 6 9% vs. 16 6 10% in alteplase and streptoki-
nase groups, respectively). Similarly, a significant decrease was
observed at 12 h in MPAP (239 6 12% vs. 234 6 20% in
alteplase and streptokinase groups, respectively), as well as in
TPR (248 6 15% vs. 249 6 19% in alteplase and streptoki-
nase groups, respectively). Changes in hemodynamic variables
were significant over time in both groups. A significant inter-
group difference was observed at 1 h (interaction treatment 3
time, p 5 0.006), showing a faster TPR improvement in the
alteplase group compared with the streptokinase group
(234 6 13% vs. 221 6 16%). At 2 h, when infusions were
completed, no significant difference persisted between the two
groups (238 6 18% vs. 231 6 19% in alteplase and strep-
tokinase groups, respectively) (Fig. 1). TPR did not decrease in
two patients in the streptokinase group. One patient (men-
tioned earlier) received an additional dose of 90 mg of
alteplase over 2 h, when the fibrinogen level increased up to 1
g/liter, with a significant decrease in TPR over 12 h (235%).
The other patient did not receive further thrombolysis and was
not referred for pulmonary embolectomy.
Residual pulmonary vascular obstruction on the 36- to
Table 2. In-Hospital Clinical Course and Adverse Events*
Alteplase
(n 5 23)
Streptokinase
(n 5 43)
In-hospital uneventful clinical course 18 (78%) 32 (74%)
Death 0 0
Blood pressure drop 1 5
Recurrent nonfatal pulmonary embolism 2 1
Bleeding complications (total) 5 (20%) 6 (16%)
Major bleeding 5 (20%) 3 (8%)
Hematoma (vascular access) 4 2
Gastrointestinal 1 1
Other important bleeding 0 3 (8%)
Hematoma (vascular access) 0 1
Hematuria 0 2
Surgical embolectomy 0 1
Septicemia 0 1
Heparin-induced thrombocytopenia 1 2
*p 5 NS for all comparisons. Data presented are number (%) of patients.
Table 3. Hemodynamic Results
HR (beats/min) CO (liters/min) MPAP (mm Hg) TPR (dyneszcm25zs) Sv#O2 (%)
rt-PA SK rt-PA SK rt-PA SK rt-PA SK rt-PA SK
Baseline 93 6 18 93 6 15 4.2 6 1.4 4.1 6 1.5 33 6 8 35 6 10 721 6 361 790 6 415 62 6 10 62 6 9
30 min 88 6 18 92 6 15 4.4 6 1.4 4.2 6 1.6 28 6 9 31 6 10 579 6 317 674 6 368 65 6 9 65 6 8
1 h 87 6 17 90 6 15 4.6 6 1.3 4.4 6 1.6 25 6 8 30 6 9 479 6 256 626 6 350 66 6 7 65 6 9
2 h 83 6 16 89 6 17 4.6 6 1.3 4.5 6 1.5 22 6 7 28 6 9 447 6 253 549 6 318 69 6 8 68 6 8
6 h 83 6 14 86 6 11 4.7 6 1.3 4.7 6 1.5 20 6 6 25 6 9 420 6 244 470 6 305 69 6 7 70 6 9
12 h 80 6 13 86 6 11 4.8 6 1.2 5.0 6 1.6 20 6 6 23 6 8 375 6 205 406 6 240 69 6 6 72 6 7
Data presented are mean value 6 SD. CO 5 cardiac output; HR 5 heart rate; MPAP 5 mean pulmonary artery pressure; rt-PA 5 recombinant tissue-type
plasminogen activator; SK 5 streptokinase; Sv#O2 5 hemoglobin saturation of mixed venous blood; TPR 5 total pulmonary resistance.
Figure 1. Evolution of TPR in 66 patients. The difference between the
two groups was significant at 1 h, but not thereafter. Data are
presented as mean value 6 SD. Solid curve 5 streptokinase (n 5 43);
dashed curve 5 alteplase (n 5 23).
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48-h lung scans was similar in the alteplase and streptoki-
nase groups (29 6 13% and 30 6 11%, respectively; p 5
NS).
Hematologic and coagulation data. There were no differ-
ences between the two groups in hematocrit or platelet count
at baseline or at 24 or 48 h. Streptokinase infusion resulted in
prolonged fibrinolytic activation, as shown by a fall of 87 6
17% in the fibrinogen level after 2 h, 84 6 12% after 6 h and
77 6 14% after 24 h. In the alteplase group, the fall in the
fibrinogen level after 2 h (72 6 25%) was significantly lower
than that observed in the streptokinase group (p 5 0.01).
Similarly, at 6 and 24 h, the magnitude of the fall in the
fibrinogen level was significantly lower in the alteplase group
than that in the streptokinase group (69 6 17% and 48 6 22%,
p 5 0.007 and p , 1025, respectively).
Follow-up data (Table 4). One-year follow-up data were
obtained in all but one patient. The average follow-up period
was 13 6 2 months. One-year event-free survival was similar in
both groups (78% in alteplase group vs. 77% in streptokinase
group, p 5 NS) (Table 3). Two deaths occurred in the alteplase
group at 6- and 8-month follow-up; they were related to cancer
in both patients, one case preexisting when the patient was
included in the trial. No events related to thromboembolic
disease occurred in the alteplase group. In contrast, late
recurrent pulmonary embolism occurred in two streptokinase-
treated patients (at 7- and 8-month follow-up) after discontin-
uation of oral anticoagulation in both patients. One
streptokinase-treated patient experienced chronic thromboem-
bolic pulmonary hypertension responsible for right heart fail-
ure. It should be noted that despite no change in right heart
hemodynamic data at the end of the thrombolytic infusion, this
patient did not receive further thrombolysis and was not
referred for pulmonary embolectomy. Most events leading to
recurrent hospital admission were related to concomitant
diseases. Bleeding complication (hematuria) occurred in only
one patient who received oral anticoagulation.
Discussion
Although no randomized trial has demonstrated that
thrombolytic therapy is capable of reducing the in-hospital
mortality rate when administered to patients with acute mas-
sive pulmonary embolism, this therapeutic option has been
widely accepted for this particular indication because it has
been shown to lead to faster right heart hemodynamic im-
provement compared with heparin. However, a recent study
based on a multicenter registry reported a significant reduction
in in-hospital overall mortality and recurrence of pulmonary
embolism in patients who underwent primary thrombolysis
compared with those initially treated with heparin alone. In
that report, thrombolytic therapy was shown, by multivariate
analysis, to be an independent predictor of survival, thus
providing the first link between hemodynamic benefits and
clinically relevant end points (5).
Similar angiographic improvement has been demonstrated
after a 2-h infusion of recombinant tissue-type plasminogen
activator or urokinase, thus suggesting that the efficacy of
thrombolysis in massive pulmonary embolism depends on the
thrombolytic regimen rather than on the type of thrombolytic
agent used (8). However, given the exponential relation that
exists between pulmonary vascular obstruction and TPR (17),
many studies assessing the efficacy of thrombolysis in acute
pulmonary embolism have addressed right heart hemodynamic
data as the most reliable surrogate end point.
Therefore, we have performed trials to assess the efficacy of
different regimens of streptokinase, because no study except
the Urokinase Streptokinase Pulmonary Embolism Trial (US-
PET) (2) has compared streptokinase with any other throm-
bolytic agent in the setting of massive pulmonary embolism
(12,18–21).
Efficacy of thrombolytic regimens. In a previous trial, we
compared a 2-h regimen of alteplase with a 12-h regimen of
streptokinase. That trial showed that the decrease in pulmo-
nary vascular resistance was achieved faster in the alteplase
group, with consistently significant intergroup differences from
30 min up to 6 h after the onset of thrombolysis (11).
In the present study comparing 2-h regimens of streptoki-
nase and alteplase, the decrease in TPR occurred again more
rapidly with alteplase than with streptokinase. Although the
difference was present up to 6 h after the onset of thrombolytic
infusion, it was only statistically significant at 1 h and not
thereafter. After 6 h, the two curves of pulmonary vascular
resistance were confounded. This faster initial improvement
did not result in better relief of pulmonary vascular obstruc-
tion, which was found to be identical 36 to 48 h after the onset
of treatment, indicating that lysis of intrapulmonary thrombus
was of the same magnitude in both treatment groups.
It is not possible to strictly compare the evolution of two
groups of patients treated in two separate trials, even with
similar inclusion criteria, demographic characteristics and ini-
tial pulmonary vascular obstruction. However, we can reason-
ably assume that infusion of streptokinase over 2 h produced
faster hemodynamic improvement than that seen over 12 h,
Table 4. One-Year Follow-Up Data
Alteplase
(n 5 23)
Streptokinase
(n 5 43)
1-yr event-free survival 18 (78%) 33 (77%)
Death (cancer) 2 0
Recurrent hospital admission 5 10
Recurrent pulmonary embolism 0 2
Chronic thromboembolic pulmonary
hypertension
0 1
Bleeding 0 1
Chest pain 1 1
Epilepsy 1 0
Polycystic kidney 0 1
Prostatic adenoma 1 2
Cholecystectomy 0 1
Cancer 2 1
Data presented are number (%) of patients.
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because the decrease in TPR at 2 h was 213 6 12% in the 12-h
regimen compared with 231 6 19% in the 2-h regimen.
Although no statistical difference in TPR was observed in
this study when both thrombolytic infusions were completed, it
would be premature to conclude equivalency between the two
thrombolytic agents for all patients with a pulmonary embo-
lism. Based on the faster hemodynamic response demonstrated
with alteplase, this thrombolytic agent might be more appro-
priate in patients with life-threatening pulmonary embolism
with cardiogenic shock, in whom the earlier the hemodynamic
improvement the better. However, the sample size and the
initial clinical presentation of the study group fail to address
the specific concern of mortality in this subset of patients.
The administered dosage of streptokinase was less than the
dosage commonly used in acute myocardial infarction. Higher
dosages or a shorter infusion period of streptokinase may be of
interest given the promising results obtained with a streptoki-
nase dosing regimen of 1.5 IU over 1 h in patients with massive
pulmonary embolism and hemodynamic instability (12). The
heparin regimen was similar between the two therapeutic
groups and was started immediately at the end of thrombolytic
infusion, as currently recommended in European thrombolytic
protocols in massive pulmonary embolism. However, data
from the GUSTO trial suggest that heparin could be given
earlier as a bolus injection at the onset of and as a perfusion
during thrombolytic therapy (14).
Safety. The bleeding complication rate was similar in both
groups and comparable to that reported in previous studies
using equivalent definitions of bleeding complications (9–
11,22). Most bleeding occurred at vascular access sites re-
quired for pulmonary angiography, known to be the major
predisposing factor for bleeding (23). However, in most cases,
the diagnosis of acute massive pulmonary embolism can be
ascertained with noninvasive studies, with a lower bleeding
rate in routine clinical practice.
The incidence of hypotension was more frequent with
streptokinase than with alteplase, as observed in previous
studies (13). Hypotension is likely to be more common if
streptokinase is administered rapidly (24), but is usually re-
versible with temporary cessation of the infusion and intrave-
nous administration of fluids.
Long-term follow-up. Few randomized trials have assessed
the potential long-term benefits of thrombolytic therapy in
acute massive pulmonary embolism (25–27). Long-term mor-
tality was attributed to underlying comorbid diseases rather
than to unresolved pulmonary embolism (28). Cancer, conges-
tive heart failure, age .60 years and chronic lung disease were
shown to be predictors of subsequent death (29). In patients
without preexisting cardiac or pulmonary disease, the reported
1-year mortality rate ranged from 3% to 9%, similar to that
observed in this trial (3%). The rate of recurrent pulmonary
embolism was 7.5% in this study (n 5 5), comparable to the
8.3% rate of recurrence at 1 year follow-up reported by Carson
et al. (29), who showed that most recurrences of embolism
occurred during the first week of follow-up and resulted in a
high mortality rate.
The incidence of chronic thromboembolic pulmonary hy-
pertension is low among patients with a history of acute
pulmonary embolism who receive appropriate anticoagulant
therapy (25,30–32). In our trial, right ventricular failure oc-
curred in one patient in whom the MPAP was 34 mm Hg 12 h
after initiation of streptokinase, with a residual lung scan
defect of 37%. According to Moser et al. (33), incomplete
thrombus dissolution leads to an aberrant path of recanaliza-
tion, leaving endothelialized residua that obstruct or signifi-
cantly narrow major pulmonary arteries, and is responsible for
severe pulmonary hypertension and progressive right ventric-
ular failure (33).
Study limitations. The primary end point of this study was
to compare hemodynamic improvement resulting from 2-h
regimens of streptokinase and alteplase. The sample size was
calculated to achieve the statistical power required for such a
comparison. However, given the size of the trial, the statistical
power of the study was clearly insufficient to address secondary
end points, such as safety, frequency of adverse events and
long-term results.
It should be noted that despite evidence of angiographic
and hemodynamic characteristics of severity, only two patients
were in cardiogenic shock at presentation. Except for those
patients, CO was maintained in the remaining 64 patients.
Therefore, our finding may apply more accurately to patients
with massive pulmonary embolism and maintained CO.
Clinical implications. The results of our study suggest that
thrombolysis occurred more rapidly over the first hour of a 2-h
infusion of alteplase than during a 2-h infusion of streptoki-
nase in patients with massive pulmonary embolism and main-
tained CO. There was no significant difference in TPR after 2 h
between the two groups, with a similar residual vascular
obstruction at 36 to 48 h. Therefore, given the low cost of
streptokinase compared with urokinase and alteplase, we can
reasonably recommend that a 2-h regimen of streptokinase be
routinely used in this setting, without obviously compromising
safety and with a similar efficacy.
We are indebted to Sophie Boucher and Susan Sherman for their help in writing
this report.
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